Urologic Oncology-Seminars and Original Investigations

Papers
(The TQCC of Urologic Oncology-Seminars and Original Investigations is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma57
Germline genetics in prostate cancer: Amidst a paradigm shift51
The role of multiparametric MRI in active surveillance for low-risk prostate cancer: The ROMAS randomized controlled trial47
Editorial Board45
Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors36
National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy35
Festschrift essay to celebrate Dr. Michael Droller35
REAL-WORLD ANALYSES OF MACE AND MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER AFTER INITIATION OF LHRH AGONISTS VS. GNRH ANTAGONIST31
COMUTATIONAL PATTERNS IN FGFR3-ALTERED NON-MUSCLE INVASIVE BLADDER CANCER INFLUENCE RECURRENCE AND PROGRESSION31
PREVALENCE OF OCCULT UROLOGIC MALIGNANCIES IN PATIENTS UNDERGOING SCREENING FOR LUNG CANCER31
APPLICATION OF THE STRATCANS CRITERIA TO THE MUSIC AS COHORT: A STEP TOWARDS RISK STRATIFIED ACTIVE SURVEILLANCE30
PREOPERATIVE RADICAL CYSTECTOMY ERAS SCREENING AND EDUCATION – PATIENT REPORTED OUTCOMES30
DECIPHER® GENOMIC CLASSIFIER SCORE ON INITIAL BIOPSY IS ASSOCIATED WITH PROGRESSION FORM ACTIVE SURVEILLANCE TO TREATMENT IN PROSTATE CANCER28
UTILITY OF C-REACTIVE PROTEIN LEVELS IN IMPROVING RISK STRATIFICATION IN METASTATIC RENAL CELL CARCINOMA26
“Published abstracts from the 24th Annual Meeting of the Society of Urologic Oncology”26
A QUALITATIVE EXPLORATION OF THE EXPERIENCE OF TRANSGENDER AND GENDER NONCONFORMING PATIENTS WITH GENITOURINARY AND GYNECOLOGIC MALIGNANCIES26
The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients25
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer25
Genetic variations related to the prostate cancer risk: A field synopsis and revaluation by Bayesian approaches of genome-wide association studies25
Predictors of discharge to home following major surgery for urologic malignancies: Results from the national surgical quality improvement program25
GROWTH OF VON HIPPEL-LINDAU (VHL)-ASSOCIATED RENAL TUMORS DURING PREGNANCY25
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens24
Guideline discordant care in patients with metastatic germ cell tumors24
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma23
Exploring prostate-specific antigen (PSA) Testing rates and screening disparities in the all of us dataset23
COVID-19 vaccination: Prioritization of at risk groups23
Managing female sexual dysfunction23
Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collabor23
Editorial Board23
NON-MUSCLE INVASIVE RECURRENCE AND MANAGEMENT DURING SURVEILLANCE IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ACHIEVE CLINICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY23
Extracellular vesicles in renal cell carcinoma: A review of the current landscape and future directions21
Multicenter study of active surveillance for small renal masses: Real world practice pattern21
Impact of the controlling nutritional status (CONUT) score on perioperative morbidity and oncological outcomes in patients with bladder cancer treated with radical cystectomy21
The centralization of bladder cancer care and its implications for patient travel distance21
Is YouTube a good resource for patients to better understand kidney cancer?21
Safety and efficacy of intravesical Bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer: A retrospective study21
Morbidity and mortality of multivisceral resection with radical nephrectomy for locally advanced renal cell carcinoma: An analysis of the National Surgical Quality Improvement Program (NSQIP) database20
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites20
The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomy20
Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer20
Carbonic anhydrase 10 functions as a tumor suppressor in renal cell carcinoma and its methylation is a risk factor for survival outcome19
Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns19
Methodological considerations for systematic review and meta-analysis of Xpert bladder cancer monitor19
Salvage local treatment for recurrent prostate cancer after focal therapy: A systematic review and meta-analysis19
Poor clinical outcomes and immunoevasive contexture in SIRPα+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients19
Cut-offs for relapse detection in men with stage I testicular germ cell tumors during active surveillance within a prospective multicentre cohort study using either raw or housekeeper normalized miR-319
Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma18
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy18
Predictive value of renal tumor contour irregularity score in pathological T3a upstaging of clinical T1 renal cell carcinoma: A multi-institutional study18
Comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: is AUC close enough to clinical practice?18
Prostate cancer outcomes disparities: Population survival analysis in an ethnically diverse nation18
Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients18
Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma18
PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors18
Radical prostatectomy readmissions: Causes, risk factors, national rates, & costs17
The impact of carcinoma in situ in ureteral margins during radical cystectomy: A case-controlled study17
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-0217
TUMOROID AND GENOMIC MODELING OF LOW GRADE INTERMEDIATE RISK BLADDER CANCER TO PREDICT INTRAVESICAL CHEMOTHERAPY RESPONSE17
PSYCHOLOGICAL RESILIENCE AND DISTRESS AMONG RADICAL CYSTECTOMY PATIENTS: A SYMPTOM DISTRESS SCALE SURVEY ANALYSIS16
RETROPERITONEAL NODAL DISTRIBUTION OF METASTATIC SEMINOMA: A CLINICAL MAPPING STUDY16
MRI-GUIDED TRANSURETHRAL ULTRASOUND ABLATION (TULSA) OF LOCALIZED PROSTATE CANCER: SINGLE INSTITUTION EXPERIENCE OF TREATMENT EFFICACY16
DEFINING THE IMPACT OF PERSONAL AND FAMILY HISTORY OF LYNCH-SYNDROME ASSOCIATED CANCERS ON CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA16
CHEST CT SHOULD REPLACE CHEST X-RAYS TO EVALUATE FOR THORACIC RENAL CELL CARCINOMA METASTASES16
FEASIBILITY AND OUTCOMES OF INTERVENTIONS TO REDUCE CYSTOSCOPY DISCOMFORT: A QUALITY IMPROVEMENT PILOT16
Radiation therapy in the management of the inguinal region in penile cancer: What's the evidence?15
UTILIZING LOW-PASS WHOLE GENOME SEQUENCING OF URINARY-TUMOR DNA TO IDENTIFY MINIMAL RESIDUAL DISEASE PRIOR TO REPEAT TRANSURETHRAL RESECTION OF BLADDER TUMOR15
Number of cores needed to diagnose prostate cancer during MRI targeted biopsy decreases after the learning curve15
IMPACT OF NODAL DISEASE IN NON-CLEAR CELL RENAL CELL CARCINOMA AND THE ROLE OF SALVAGE LYMPH NODE RESECTION15
COMPARING WHITE LIGHT VERSUS BLUE LIGHT CYSTOSCOPY RECURRENCE OUTCOMES AMONG NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS IN AN EQUAL ACCESS SETTING: A PROPENSITY SCORED MATCHED ANALYSIS15
Multimodality treatment of penile cancer: Part 215
INTENSIFIED MRI-BASED PROSTATE CANCER SCREENING IN GERMLINE CARRIERS OF RARE PATHOGENIC VARIANTS: INTERIM RESULTS FROM THE INITIAL SCREENING ROUND OF THE PROGRESS STUDY15
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis15
A novel predictive model for pelvic lymph node metastasis in patients with penile cancer: A multi-institutional study14
Exploration of biomarkers from a pilot weight management study for men undergoing radical prostatectomy14
CLINICAL PROGRESSION OF PROSTATE CANCER FROM ACTIVE SURVEILLANCE IS PREDICTED BY DECIPHER® GENOMIC CLASSIFIER SCORE ON INDEX BIOPSY INDEPENDENT FROM RISK ASSESSMENT BY MRI CHARACTERISTICS14
IMMEDIATE LYMPHATIC RECONSTRUCTION WITH LYMPHATICOVENOUS BYPASS CREATION AFTER BILATERAL INGUINAL LYMPH NODE DISSECTION FOR PENILE CANCER: A CASE SERIES14
MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer14
Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities14
AUTOMATED NEPHROMETRY SCORES THROUGH DIRECT PREDICTION OF EACH COMPONENT14
EDARADD silencing suppresses the proliferation and migration of bladder cancer cells14
Prospective validation of the Kaiser Permanente prostate cancer risk calculator in a contemporary, racially diverse, referral population14
Artificial intelligence in urological oncology: An update and future applications14
FACTORS ASSOCIATED WITH PROSTATE CANCER SCREENING AMONG HISPANIC MEN: RESULTS FROM HISPANIC COMMUNITY HEALTH STUDY/STUDY OF LATINOS (HCHS/SOL)14
Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non–muscle invasive bladder cancer13
Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor13
Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity13
Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy13
Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma13
Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prosp13
Prospective validation of clino-radio-pathological risk scoring system (CRiSS) for prediction of inguinal lymph-nodes metastasis in squamous cell carcinoma of penis13
Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer13
How to manage patients with suspected upper tract urothelial carcinoma in the pandemic of COVID-19?13
Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma13
Implementation of a nonopioid protocol following robot-assisted radical cystectomy with intracorporeal urinary diversion13
Multivariate analysis of the parameters affecting the choice of surgical treatment for patients with localized renal cell carcinoma (RCC)12
Cover 2 - Masthead12
Comparison of microwave ablation and partial nephrectomy for T1a small renal masses12
Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients12
A comparison of outcomes between transperitoneal and retroperitoneal robotic assisted partial nephrectomy in patients with completely endophytic kidney tumors12
Conditional survival of stage III non-seminoma testis cancer patients12
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety12
Is hypofractionation acceptable for prostate bed radiotherapy?12
Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT)12
Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance12
The impact of bladder cuff excision on outcomes after nephroureterectomy for upper tract urothelial carcinoma: An analysis of the ROBUUST 2.0 registry12
Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma12
Table of Contents12
Impact of the time elapsed between prostate biopsy and surgery on the accuracy of nomograms predicting lymph node invasion in patients with clinically localized prostate cancer12
Healthcare costs and resource utilization associated with renal cell carcinoma among older Americans: A longitudinal case-control study using the SEER-Medicare data12
Molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs regulating lymphatic metastasis of bladder cancer12
Assessing the impact of lymphovascular invasion on overall survival in surgically treated renal cell carcinoma patients: A nationwide cohort analysis11
Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus11
Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection11
Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma11
Pathologic and Short-Term Oncologic Outcomes of Prostate Cancer Patients Following Transvesical Robot-Assisted Radical Prostatectomy11
Mutational landscape of non-muscle-invasive bladder cancer11
Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer11
Development of a specific supportive care needs scale for radical cystectomy patients and its reliability and validity test11
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention11
The effect of metastasectomy on overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis11
Characteristics Contributing to Survival Differences Between Black and White Patients Following Cystectomy11
Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer11
Bilateral inguinal lymphadenectomy using simultaneous double laparoscopies for penile cancer: A retrospective study11
Comparative analysis of salvage partial nephrectomy versus radical nephrectomy after the failure of initial partial nephrectomy11
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy11
Disparities in access to high-volume centers and in hospital discharge status following radical cystectomy in Florida11
HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume center11
Biodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer patients11
Uptake of re-resection in T1 bladder cancer: An interrupted population-based time series analysis among different groups of surgeons11
The 5-item frailty index predicts 30-day morbidity and mortality in radical nephrectomy patients: A propensity matched analysis11
Contemporary outcomes for robotic radical cystectomy and intracorporeal neobladder urinary diversion10
PHASE 3 MK-5684-004 STUDY OF CYP11A1 INHIBITOR OPEVESOSTAT VERSUS NEXT-GENERATION HORMONAL AGENT (NHA) SWITCH IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER 1 PRIOR NHA10
A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers10
CHANGES IN PROSTATE SPECIFIC ANTIGEN SCREENING FOLLOWING THE 2018 UNITED STATES PREVENTIVE SERVICES TASK FORCE GUIDELINES AND THROUGH THE COVID-19 PANDEMIC10
Cover 2 - Masthead10
PSMA PET/CT-DETECTED MESORECTAL LYMPH NODE METASTASES: TREATMENT OUTCOMES AND CLINICAL IMPLICATIONS10
Device-related complications during renal cryoablation: insights from the Manufacturer and User Facility Device Experience (MAUDE) database10
Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients10
Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma10
Prostate magnetic resonance imaging utilization and its relationship with advanced prostate cancer detection10
Designing lean, efficient clinical trials is an ethical imperative: the fragility index should not be used in the design of randomized clinical trials10
SURVIVAL PATTERNS BASED ON SITE-SPECIFIC VISCERAL METASTASIS IN METASTATIC PROSTATE CANCER PATIENTS: ARE OUTCOMES OF VISCERAL METASTASES THE SAME?10
Acetyl-CoA synthetase 2 enhances tumorigenesis and is indicative of a poor prognosis for patients with renal cell carcinoma10
LARGE LANGUAGE MODEL FOR PROVIDING PATIENT-FOCUSED GUIDANCE FOLLOWING RADICAL PROSTATECTOMY10
The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy10
The effect of race on stage at presentation and survival in upper tract urothelial carcinoma10
Association of heavy metals and trace elements in renal cell carcinoma: A case-controlled study10
Genitourinary toxicity in patients receiving TURP prior to hypofractionated radiotherapy for clinically localized prostate cancer: A scoping review10
Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma10
Unraveling the BMI paradox in different renal cortical tumors: insights from the INMARC registry10
LOW-GRADE AND HIGH-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RESPOND DIFFERENTLY TO BACILLUS CALMETTE-GUÉRIN AND GEMCITABINE-DOCETAXEL10
“Robotic fatigue?” – The impact of case order on positive surgical margins in robotic-assisted laparoscopic prostatectomy10
Editorial Board10
BLOOD-BASED LIQUID BIOPSY IN DIAGNOSIS, SURVEILLANCE, AND PROGNOSIS OF PATIENTS WITH PRIMARY UPPER TRACT UROTHELIAL CARCINOMA10
State of the Art: The Microbiome in Bladder Cancer10
Masculinity stigma and metastatic prostate cancer: A review with a focus on Latin America10
The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-in10
Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer: An Analysis of Real-World Practice Patterns from the CancerLinQ Database10
Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC9
The role of autophagy dysregulation in low and high-grade nonmuscle invasive bladder cancer: A survival analysis and clinicopathological association9
THE PROGNOSTIC ROLE OF THE NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS TREATED WITH INTRAVESICAL GEMCITABINE AND DOCETAXEL9
Annular-shaped stenosis in the ureter: Caution should be taken9
Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma9
Opioid prescription following radical orchiectomy associated with new persistent opioid use9
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide9
MAPPING PATTERNS OF RECURRENCE AFTER SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH METASTATIC PROSTATE CANCER9
THE PROGNOSTIC SIGNIFICANCE OF CIRCULATING TUMOR DNA IN PATIENTS WITH POSITIVE LYMPH NODE DISEASE AFTER ROBOTIC-ASSISTED RADICAL CYSTECTOMY9
Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients9
Intra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence9
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment9
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer9
INCIDENCE AND PATHOLOGIC OUTCOMES OF CYSTECTOMY IN PATIENTS WITH BACILLUS CALMETTE-GUÉRIN-UNRESPONSIVE NON–MUSCLE-INVASIVE BLADDER CANCER WITH CARCINOMA IN SITU FOLLOWING TREATMENT WITH NADOFARAGENE F9
HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY OR OTHER SUBTYPES NOT A PREDICTOR FOR PROGRESSION IN BCG-TREATED PATIENTS9
Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center9
QUANTIFYING THE BENEFIT OF SALVAGE RADIATION THERAPY FOR BIOCHEMICALLY RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY9
The efficacy of adjuvant mitotane therapy and radiotherapy following adrenalectomy in patients with adrenocortical carcinoma: A systematic review and meta-analysis9
The relationship between BCG immunotherapy and oxidative stress parameters in patients with nonmuscle invasive bladder cancer9
2023 Star Reviewers for Urologic Oncology9
EARLY POSTOPERATIVE CANCER-SPECIFIC DEATH AMONGST PATIENTS WITH HIGH-RISK NON-METASTATIC CLEAR CELL RENAL CELL CARCINOMA: REFINING RISK STRATIFICATION TO OPTIMIZE SELECTION FOR ADJUVANT THERAPY9
A PHASE IIB RANDOMIZED PLACEBO-CONTROLLED TRIAL TESTING A LONG-CHAIN OMEGA-3 FATTY ACID MAG-EPA DIETARY SUPPLEMENT ON PROSTATE CANCER AND GUT MICROBIOME9
THE NONCANONICAL WNT PATHWAY (FYN/STAT3) ACTIVATED BY YY1 PROMOTES THE NEUROENDOCRINE DIFFERENTIATION OF PROSTATE CANCER CELLS.9
Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET9
THE ASSOCIATION BETWEEN HEALTH LITERACY AND ALL-CAUSE MORTALITY IN UROLOGIC CANCER PATIENTS9
INTRAVESICAL AUTOLOGOUS TIL THERAPY IN BCG-EXPOSED NMIBC: A REPORT OF EARLY SAFETY AND EFFICACY FINDINGS9
Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial9
LEVEL OF NODAL METASTASIS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY AND LYMPHADENECTOMY: IS THERE A ROLE OF EXTENDED LYMPHADENECTOMY IN THE POST-S1011 ERA?9
Deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: A systematic review and patient-level meta-analysis8
Investigating the pattern of prostate specific antigen screening among E-cigarette smokers within the behavioral risk factor surveillance system8
Artificial intelligence in prostate cancer: Definitions, current research, and future directions8
“I was in a very deep, dark place... I wasn't prepared for that”: A qualitative assessment of the emotional well-being needs of patients undergoing cystectomy8
Cover 2 - Masthead8
EARLY ONCOLOGIC OUTCOME AND PSA KINETICS FOLLOWING IRREVERSIBLE ELECTROPORATION IN MEN WITH PROSTATE CANCER8
Contemporary morbidity and mortality of open versus robotic cystectomy for bladder cancer: An analysis of the National Surgical Quality Improvement Program (NSQIP) procedure targeted cystectomy databa8
PIVOT-006: A PHASE 3, RANDOMIZED STUDY OF ADJUVANT INTRAVESICAL CRETOSTIMOGENE GRENADENOREPVEC VERSUS SURVEILLANCE FOR THE TREATMENT OF INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER8
CARCINOMA IN SITU AND URINARY CYTOLOGY AS AN INDICATOR OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BCG8
Predictive factors for recurrence and outcomes in T1a renal cell carcinoma: Analysis of the INMARC (International Marker Consortium for Renal Cancer) database8
Current controversies on the role of lymphadenectomy for testicular cancer for the journal: Urologic Oncology: Seminars and Original Investigations for the special seminars section on the role of lymp8
Clinically significant prostate cancer detection rate in biopsy-naïve patients with mpMRI and microultrasound topographically discordant lesions: A single-center retrospective analysis8
Avoiding “Needless” nephrectomy: What is the role of small renal mass biopsy in 2024?8
Diagnostic yield of upper tract imaging performed for hematuria screening: Results from a national, privately-insured cohort8
Steroidogenesis in castration-resistant prostate cancer8
Introduction to the 25th anniversary issue8
Cover 2 - Masthead8
DEVELOPMENT AND EXTERNAL VALIDATION OF A LOCAL PELVIC RECURRENCE RISK SCORE AFTER RADICAL CYSTECTOMY: IDENTIFYING THE IDEAL CANDIDATE FOR ADJUVANT RADIATION CLINICAL TRIALS8
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer8
Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis8
GRADE AND VOLUME PROGRESSION AND ITS ASSOCIATION WITH THE DECIPHER GENOMIC CLASSIFIER USING PATIENTS ENROLLED IN A PROSPECTIVE ACTIVE SURVEILLANCE PROTOCOL8
Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis8
Non-muscle-invasive bladder cancer: An overview of potential new treatment options8
Update on organ preserving surgical strategies for penile cancer8
Prognostic significance of pathologic response to neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder with histologic subtype8
Editorial Board8
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer8
Re: Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer. Yanagisawa T, Sato S, Hayashida Y, Okada Y, Fukuokaya W, Iwatani K, et al. J Urol Oncol. 2023;41(12):484.e7-484.e158
Bladder cancer patient and provider perspectives on smoking cessation8
THE DISPARITY OF LYMPH NODE DISSECTION IN T2+N0M0 STAGE PENILE SQUAMOUS CELL CARCINOMA PATIENTS8
25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology8
The CAG-triplet in the androgen receptor gene and single-nucleotide polymorphisms in androgen pathway genes in patients with concomitant bladder and prostate cancer8
SEQUENTIAL ENDOLUMINAL GEMCITABINE AND CABAZITAXEL WITH SYSTEMIC PEMBROLIZUMAB FOR RECURRENT NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE UPPER AND LOWER URINARY TRACTS8
COMPARING ACTIVE SURVEILLANCE AND WATCHFUL WAITING AND RADICAL TREATMENT USING MACHINE LEARNING MODELS AMONG PROSTATE CANCER PATIENTS8
Epigenetics regulation of prostate cancer: Biomarker and therapeutic potential8
A machine learning approach to predict progression on active surveillance for prostate cancer8
HOME INSTILLATION OF UGN-102 FOR PRIMARY CHEMOABLATION OF RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER: A SINGLE-ARM, OPEN-LABEL, PHASE 3B TRIAL7
Clinician interest in clinical decision support for PSA-based prostate cancer screening7
Global trends and regional variations in PCa burden: A focus on China's rapid growth7
Festschrift honoring Michael Droller7
DEVELOPMENT AND TESTING OF A CUSTOM NANOSTRING RNA CODESET FOR MUSCLE-INVASIVE BLADDER CANCER UTILIZING TCGA SUBTYPING (SWOG S1011)7
Corrigendum to < Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer>, urologic oncology: Seminars and original inve7
GENE EXPRESSION DIFFERENCES AND PATHWAY ACTIVATION BY RACE IN ERG+ PROSTATE CANCERS: IMPLICATIONS FOR EQUITABLE CANCER CARE7
CYTOREDUCTIVE NEPHRECTOMY IS ASSOCIATED WITH IMPROVED SURVIVAL FOR SARCOMATOID METASTATIC RENAL CELL CARCINOMA PATIENTS TREATED BEFORE OR AFTER SURGERY WITH IMMUNE CHECKPOINT INHIBITORS7
Cover 2 - Masthead7
Michael Droller: An appreciation, for his Festschrift 20247
STIMULATED RAMAN HISTOLOGY AND ARTIFICIAL INTELLIGENCE ALLOWS FOR PREDICTION OF PROSTATE CANCER EXTRAPROSTATIC EXTENSION AND POSITIVE SURGICAL MARGIN DURING RADICAL PROSTECTOMY7
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions7
Influence of radical prostatectomy on miRNA dynamics in urine extracellular vesicles7
Cover 2 - Masthead7
CONCOMITANT SECOND-GENERATION HORMONE THERAPY WITH RADIUM-223 IN THE THIRD-LINE SETTING: DOES IT IMPROVE OVERALL SURVIVAL?7
ROLE OF TUMOR MICROENVIRONMENT DERIVED NRG1 IN ANDROGEN RESISTANCE: IMPLICATIONS FOR A NOVEL PROSTATE CANCER TREATMENT STRATEGY7
EVALUATING CLINICAL OUTCOMES AND THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN PLASMACYTOID UROTHELIAL CARCINOMA: INSIGHTS FROM A COMBINED NATIONAL AND INSTITUTIONAL SERIES7
Table of Contents7
RISK FACTORS FOR PROGRESSION IN PATIENTS WITH POST-BCG RECURRENT NMIBC7
Cause-specific mortality among patients with renal cell carcinoma in the United States from 2000 to 20187
The additive value of mpMRI on prostate cancer detection: Comparison between patients with and without a suspicious digital rectal examination (DRE)7
RADIATION THERAPY AND IRREVERSIBLE ELECTROPORATION (RTIRE) FOR INTERMEDIATE RISK PROSTATE CANCER: A PHASE II ONGOING TRIAL7
Editorial Board7
SUBOPTIMAL REPORTING OF ADVERSE EVENTS IN RCTs SUPPORTING BLADDER CANCER CLINICAL PRACTICE GUIDELINES7
Cover 2 - Masthead7
CONCORDANCE BETWEEN CLINICAL AND PATHOLOGIC STAGING OF T2A-B AND T3A RENAL CELL CARCINOMA: IMPLICATIONS FOR FUTURE PERIOPERATIVE CLINICAL TRIALS7
Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis7
Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma7
0.10122609138489